This phase I trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging works in treating patients with kidney cancer. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT, may help find and diagnose kidney cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT02160925.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. To investigate the utility of technetium Tc-99m sestamibi (99mTc-sestamibi) single-photon emission computed tomography/x-ray computed tomography (SPECT/CT) imaging for the preoperative diagnosis of renal oncocytoma.
OUTLINE:
Within 4 weeks of surgery, patients receive technetium Tc-99m sestamibi injection and then undergo SPECT/CT over 1 hour.
Lead OrganizationJohns Hopkins University/Sidney Kimmel Cancer Center
Principal InvestigatorMohamad E. Allaf
